Ionis Pharmaceuticals Drops Another After Phase 3 Setback
Ionis Pharmaceuticals dropped again after a Phase 3 failure in transthyretin amyloid cardiomyopathy, triggering a bro...
Timing matters: knowing when to review your budget helps you adjust before problems arise. This overview covers effective review moments.
17,852 articlesIonis Pharmaceuticals dropped again after a Phase 3 failure in transthyretin amyloid cardiomyopathy, triggering a bro...
The FHFA want to remove reputational harm as a trigger for suspending firms dealing with Fannie Mae, Freddie Mac, and...
Mitsubishi closed a $7.5 billion acquisition of Aethon Energy's U.S. gas assets, creating Adamas Energy in Dallas. Th...
A high-net-worth retiree confronts a doubled Medicare Part B premium after a two-year IRMAA lookback on an IRA withdr...
A 72-year-old retiree confronts a surprise $19,000 tax bill on his first Required Minimum Distribution, underscoring ...
Galaxy Digital announced up to $5 million in funding to accelerate Bitcoin's transition to quantum-resistant security...
New consolidation options are rolling out in 2026 as rates hold steady. Borrowers weigh relief from payments against ...
Broadcom sits at the crossroads of AI infrastructure and traditional networking. Here are three grounded predictions ...
When a smart-home name rallies, traders pay attention. This piece breaks down why resideo technologies stock popped o...
Two compelling reasons berkshire hathaway stock could shine in any market. This piece breaks down the moat, cash flow...
On Holding's stock has caught the eye of many long-term investors who pay attention to fundamentals rather than short...
AI is reshaping how businesses operate. This guide argues why a select software stock fits a once-in-a-decade opportu...